Role of systemic therapy

Matthew J. Reilley; Gauri R. Varadhachary

doi:10.1007/978-3-319-22780-1_6

Role of systemic therapy

Matthew J. Reilley, Gauri R. Varadhachary

GI Medical Oncology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Management of resectable and borderline resectable pancreatic adenocarcinoma (BRPC) represents a significant challenge. Unfortunately, in most patients, PDAC is a systemic disease at presentation. Even in the presence of excellent perioperative supportive care and low mortality in high-volume centers, approximately 80 % of patients who undergo resection will develop metastases and die of their disease within 5 years [1, 2]. This is because most patients likely have micrometastatic disease at the time of attempted curative resection [3].

Original language	English (US)
Title of host publication	Multimodality Management of Borderline Resectable Pancreatic Cancer
Publisher	Springer International Publishing
Pages	91-106
Number of pages	16
ISBN (Electronic)	9783319227801
ISBN (Print)	9783319227795
DOIs	https://doi.org/10.1007/978-3-319-22780-1_6
State	Published - Dec 10 2015

Keywords

Borderline resectable pancreatic cancer
FOLFIRINOX
Gemcitabine/abraxane
Neoadjuvant chemotherapy
Preoperative chemotherapy

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-319-22780-1_6

Cite this

@inbook{0088de916d244f3fa1d9ece2a5452a2b,

title = "Role of systemic therapy",

abstract = "Management of resectable and borderline resectable pancreatic adenocarcinoma (BRPC) represents a significant challenge. Unfortunately, in most patients, PDAC is a systemic disease at presentation. Even in the presence of excellent perioperative supportive care and low mortality in high-volume centers, approximately 80 % of patients who undergo resection will develop metastases and die of their disease within 5 years [1, 2]. This is because most patients likely have micrometastatic disease at the time of attempted curative resection [3].",

keywords = "Borderline resectable pancreatic cancer, FOLFIRINOX, Gemcitabine/abraxane, Neoadjuvant chemotherapy, Preoperative chemotherapy",

author = "Reilley, {Matthew J.} and Varadhachary, {Gauri R.}",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2016.",

year = "2015",

month = dec,

day = "10",

doi = "10.1007/978-3-319-22780-1_6",

language = "English (US)",

isbn = "9783319227795",

pages = "91--106",

booktitle = "Multimodality Management of Borderline Resectable Pancreatic Cancer",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Role of systemic therapy

AU - Reilley, Matthew J.

AU - Varadhachary, Gauri R.

N1 - Publisher Copyright: © Springer International Publishing Switzerland 2016.

PY - 2015/12/10

Y1 - 2015/12/10

N2 - Management of resectable and borderline resectable pancreatic adenocarcinoma (BRPC) represents a significant challenge. Unfortunately, in most patients, PDAC is a systemic disease at presentation. Even in the presence of excellent perioperative supportive care and low mortality in high-volume centers, approximately 80 % of patients who undergo resection will develop metastases and die of their disease within 5 years [1, 2]. This is because most patients likely have micrometastatic disease at the time of attempted curative resection [3].

AB - Management of resectable and borderline resectable pancreatic adenocarcinoma (BRPC) represents a significant challenge. Unfortunately, in most patients, PDAC is a systemic disease at presentation. Even in the presence of excellent perioperative supportive care and low mortality in high-volume centers, approximately 80 % of patients who undergo resection will develop metastases and die of their disease within 5 years [1, 2]. This is because most patients likely have micrometastatic disease at the time of attempted curative resection [3].

KW - Borderline resectable pancreatic cancer

KW - FOLFIRINOX

KW - Gemcitabine/abraxane

KW - Neoadjuvant chemotherapy

KW - Preoperative chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85012170386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012170386&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-22780-1_6

DO - 10.1007/978-3-319-22780-1_6

M3 - Chapter

AN - SCOPUS:85012170386

SN - 9783319227795

SP - 91

EP - 106

BT - Multimodality Management of Borderline Resectable Pancreatic Cancer

PB - Springer International Publishing

ER -

Role of systemic therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this